Guiding Hematologic Care with Genetic Testing

• Date :
• 5    
  0

A Personalized Prediction Model for MDS

• Date :
• 2    
  0

Promising Cardiac and Renal Responses with NEOD001 in Patients with AL Amyloidosis

• Date :
• 1    
  0

Highlights of the 2015 ASH Meeting on Hematologic Malignancies

• Date :
• 1    
  0

Expanding CAR T Cells to Treat Myeloma

• Date :
• 1    
  0

Glasdegib and New Directions in Myelofibrosis Treatment

• Date :
• 1    
  0

Preventing Progression from Smoldering to Symptomatic Myeloma

• Date :
• 0    
  0

A Rapid Screening Test for Sickle Cell Disease

• Date :
• 0    
  0

A New Treatment Option for PNH?

• Date :
• 0    
  0

Rivaroxaban Prevents Cancer-Associated VTE

• Date :
• 0    
  0

Ibrutinib Outperforms Chemoimmunotherapy in CLL

• Date :
• 0    
  0

AMG 330 Takes a BiTE out of Relapsed/Refractory AML

• Date :
• 0    
  0

Evaluating a Venetoclax and Carfilzomib Combination in Myeloma

• Date :
• 0    
  0

LMWH Bridging for Patients at High Risk for Arterial Thromboembolism

• Date :
• 0    
  0

Is Luspatercept a New Option for Patients With MDS?

• Date :
• 0    
  0

Brentuximab Vedotin Plus AVD

• Date :
• 0    
  0

Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL

• Date :
• 0    
  0

Complete Response at 30 Months: A Surrogate for PFS in First-Line Follicular Lymphoma

• Date :
• 0    
  0

Options for Treating the High-Risk APL Patient

• Date :
• 0    
  0

CLL-IPI: A New and Improved Staging System for CLL?

• Date :
• 0    
  0

Ruxolitinib in CMML: Study Shows Promising Results

• Date :
• 0    
  0

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

• Date :
• 0    
  0

New Biomarkers and Prognostic Indicators in Leukemia and MDS

• Date :
• 0    
  0

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

• Date :
• 0    
  0

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

• Date :
• 0    
  0

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients

• Date :
• 0    
  0

Predicting Hospitalizations, ER Visits Among CLL Patients

• Date :
• 0    
  0

Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL

• Date :
• 0    
  0

The Future of Clinical and Translational Research in Hematologic Malignancies

• Date :
• 0    
  0

Collaborative Care Delivery Reduces Travel Burden for AML Patients

• Date :
• 0    
  0

Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?

• Date :
• 0    
  0

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

• Date :
• 0    
  0

Newly Approved Drugs: How Should Do We Use Them in the Clinic?

• Date :
• 0    
  0

Eligibility Criteria Not Associated with Adverse Events in RCTs

• Date :
• 0    
  0

Controversy over Quality

• Date :
• 0    
  0

Optimizing Therapy in Sickle Cell Disease

• Date :
• 0    
  0

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

• Date :
• 0    
  0

New Approaches in CLL and Prolymphocytic Leukemia

• Date :
• 0    
  0

Predicting Prognosis in Myelodysplastic Syndromes

• Date :
• 0    
  0

Evolving Issues in Anticoagulation

• Date :
• 0    
  0

Ixazomib Extends PFS in the TOURMALINE-MM1 Trial

• Date :
• 0    
  0

Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma

• Date :
• 0    
  0

Induction Chemotherapy for AML: Understanding the Patient Experience

• Date :
• 0    
  0

The PROs of Patient-Reported Outcomes

• Date :
• 0    
  0

Improving Quality of VTE Care

• Date :
• 0    
  0

Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL

• Date :
• 0    
  0

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior

• Date :
• 0    
  0

The Balancing Act of Caring for Older Patients with Hemophilia

• Date :
• 0    
  0

Rivaroxaban in Cancer-Associated VTE

• Date :
• 0    
  0

Multiple Advances in Multiple Myeloma

• Date :
• 0    
  0

Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?

• Date :
• 0    
  0

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

• Date :
• 0    
  0

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

• Date :
• 0    
  0

Bortezomib Leads to More Complete Remissions

• Date :
• 0    
  0

For Older AML Patients

• Date :
• 0    
  0

TOURMALINE-MM3 and 4

• Date :
• 0    
  0

CASTOR Trial: Daratumumab Combination Doubles

• Date :
• 0    
  0

SL-401: An Encouraging Option for Patients

• Date :
• 0    
  0

Study Finds Thrombosis Risk Changes

• Date :
• 0    
  0

CPX-351: A Potential Game-Changer for Older Patients

• Date :
• 0    
  0

COMFORT: Five-Year Outcomes of Ruxolitinib

• Date :
• 0    
  0

Venetoclax Plus Hypomethylating Agents

• Date :
• 0    
  0

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

• Date :
• 0    
  0

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

• Date :
• 0    
  0

The Changing Definition of “High-Risk” CLL

• Date :
• 0    
  0

Overlapping Myeloma and CLL: Double Trouble?

• Date :
• 0    
  0

Improving Classification in High-Grade MDS

• Date :
• 0    
  0

Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma

• Date :
• 0    
  0

Treating Highly Aggressive Lymphomas

• Date :
• 0    
  0

How Do TP53 Mutation Characteristics Affect MDS Outcomes?

• Date :
• 0    
  0

Ibrutinib and Atrial Fibrillation Risk in RCTs

• Date :
• 0    
  0

How Can We Enroll More Young Patients in Clinical Trials?

• Date :
• 0    
  0

Treating Myelofibrosis After Ruxolitinib “Failure

• Date :
• 0    
  0

Nivolumab Moves to Hematology

• Date :
• 0    
  0

Attempting to Reduce Chemotherapy Burden in Children With ALL

• Date :
• 0    
  0

Selinexor Plus Low-Dose Dexamethasone in “Penta-Refractory

• Date :
• 0    
  0

New Recombinant Factors for von Willebrand Disease

• Date :
• 0    
  0

Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

• Date :
• 0    
  0

Continuing to Evaluate Pacritinib for Myelofibrosis

• Date :
• 0    
  0

Ibrutinib in Chronic Graft-Versus-Host Disease

• Date :
• 0    
  0

GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma

• Date :
• 0    
  0

Encouraging Results for CAR T-Cells in Refractory DLBCL

• Date :
• 0    
  0

Not Just CRISPR: Changing Biology Through Gene-Editing

• Date :
• 0    
  0

Prolonging Platelet Shelf-Life With DMSO

• Date :
• 0    
  0

Changing the Delivery of Bleeding Prevention for Hemophilia Patients

• Date :
• 0    
  0

The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

• Date :
• 0    
  0

Passing the Checkpoint With New Approaches to Immunotherapy

• Date :
• 0    
  0

Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

• Date :
• 0    
  0

Denosumab Versus ZA for Myeloma-Related Bone Disease

• Date :
• 0    
  0

Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

• Date :
• 0    
  0

Multidisciplinary Care Saves Lives Among Pregnant Women with SCD in Ghana

• Date :
• 0    
  0

New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML

• Date :
• 0    
  0

Bendamustine Plus Rituxmab Outperforms R-CHOP In Long-Term BRIGHT Follow-up

• Date :
• 0    
  0

Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

• Date :
• 0    
  0

Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

• Date :
• 0    
  0

Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALL

• Date :
• 0    
  0

Bendamustine-Rituximab "StiL" Beats R-CHOP for Indolent Lymphomas

• Date :
• 0    
  0

Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

• Date :
• 0    
  0

Enasidenib Shows "Encouraging" Efficacy in IDH2-Mutated AML

• Date :
• 0    
  0

CAR T-Cell Therapy in Relapsed/Refractory NHL

• Date :
• 0    
  0

Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell ALL

• Date :
• 0    
  0

Sickle Cell Patients Are Innocent Victims of the Opioid Epidemic

• Date :
• 0    
  0

TET2 Mutations Predict Cardiovascular Risk in MDS and CMML

• Date :
• 0    
  0

BLU-285 Active, Well-Tolerated in Advanced Systemic Mastocytosis

• Date :
• 0    
  0

Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

• Date :
• 0    
  0

Examining a New Indication for Romiplostim

• Date :
• 0    
  0

Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

• Date :
• 0    
  0

Does Rituximab Improve Survival in CNS Lymphoma?

• Date :
• 0    
  0

Advancing CAR T-Cell Therapy for Myeloma

• Date :
• 0    
  0

How Does Smoking Increase MDS Risk?

• Date :
• 0    
  0

Tisagenlecleucel Promising in Relapsed/Refractory DLBCL

• Date :
• 0    
  0

Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin Lymphoma

• Date :
• 0    
  0

November 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

October 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

September 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

July 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

June 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

May 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

April 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

March 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

February 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

January 2018 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

December 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

November 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

October 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

September 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

August 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

July 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

June 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

May 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

April 2017 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

March 2017 VRC QA Webinar

• Date :
• 0    
  0

February 2017 VRC QA Webinar

• Date :
• 0    
  0

January 2017 VRC QA Webinar

• Date :
• 0    
  0

December 2016 VRC QA Webinar

• Date :
• 0    
  0

October 2016 VRC QA Webinar

• Date :
• 0    
  0

September 2016 VRC QA Webinar

• Date :
• 0    
  0

August 2016 Trauma Verification Q&A Web Conference

• Date :
• 0    
  0

July 2016 VRC QA Webinar

• Date :
• 0    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3380    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date :
• 4963    
  0

The European Hematology Association - EHA 2023

• Date :
• 8092    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date :
• 12637    
  0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

• Date :
• 9346    
  7